LifeMD Inc.

Company Overview

Business Model: LifeMD, Inc. is a direct-to-patient telehealth company that provides high-quality, cost-effective, and convenient virtual and in-home healthcare. The company's proprietary technology platform integrates a 50-state medical group, a nationwide pharmacy network (including a wholly-owned affiliated commercial pharmacy), nationwide laboratory and diagnostic testing capabilities, a fully integrated electronic medical records (EMR) system, and a patient care and service call center. Revenue is primarily generated through subscription-based telehealth clinical services and prescription/over-the-counter (OTC) treatments. Additionally, LifeMD, Inc. holds a 73.3% majority ownership in WorkSimpli Software LLC, a software as a service platform for document services.

Market Position: LifeMD, Inc. operates in a rapidly evolving and competitive telehealth market, addressing largely unaddressed or underserved healthcare needs. The company positions itself with a patient-centric approach, emphasizing quality of care, a dedicated provider network, and a vertically integrated care platform. Key competitive strengths include its 50-state affiliated medical group, industry-leading telehealth technology, a wholly-owned affiliated commercial pharmacy, flexible patient payment options (including increasing commercial and Medicare insurance capabilities), an in-house patient service and call center, robust CRM and patient acquisition/retention capabilities leveraging AI, and a compliance-first mindset. As of December 31, 2024, LifeMD, Inc. treats approximately 275,000 active patient subscribers and has served approximately 1,118,000 customers and patients since inception.

Recent Strategic Developments:

• GLP-1 Weight Management Offering: Launched in April 2023, this program provides primary care, metabolic coaching, lab work, and GLP-1 prescriptions (as medically appropriate). It had over 75,000 patient subscribers as of December 31, 2024. In September 2024, the program expanded to include a personalized non-GLP-1 treatment plan with metformin, bupropion, and topiramate.
• Vertically Integrated Pharmacy: In November 2024, LifeMD, Inc. opened a 22,500-square-foot wholly-owned affiliated commercial pharmacy in Lancaster, PA, designed to fill up to 5,000 daily prescriptions. As of Q1 2025, it is licensed in 49 states and shipping up to 20,000 orders per month, with plans to build non-sterile compounding capabilities in H1 2025. This is projected to yield $5 million in annualized expense savings.
• Commercial Health Insurance Acceptance: In June 2024, LifeMD, Inc. began accepting commercial insurance for virtual primary care services, including weight management, with a goal of broad nationwide coverage by the end of 2025. Medicare enrollment is expected in the first half of 2025.
• B2B Telehealth Partnerships:
  • Withings, Inc.: Partnership executed in May 2024 to provide GLP-1 weight-loss patients with in-home health monitoring devices (Body Pro 2 scale, BPM Connect Pro blood pressure monitor) for near real-time patient data.
  • Ash Wellness: Partnership launched in May 2024 for at-home, self-collection laboratory health testing, initially for the Weight Management Program, with plans for broader clinical use.
  • Medifast, Inc.: Collaboration initiated in December 2023, where Medifast, Inc. utilizes LifeMD, Inc.'s platform to provide its clients access to a clinically supported weight management program, including GLP-1 medications. Medifast, Inc. committed $10 million to support the collaboration and platform enhancements.
  • ASCEND Therapeutics, LLC: Partnership agreement executed in September 2023 to provide integrated telehealth services to improve access to EstroGel®.
• WorkSimpli Software LLC Ownership: As of December 31, 2024, LifeMD, Inc.'s ownership interest in WorkSimpli Software LLC is 73.3%.

Geographic Footprint: LifeMD, Inc. provides services and products across all 50 states, the District of Columbia, and Puerto Rico. International net revenues totaled $14.9 million for the year ended December 31, 2024, primarily from the WorkSimpli Software LLC segment. The company operates its headquarters in New York, New York, a marketing and sales center in Huntington Beach, California, a patient care center in Greenville, South Carolina, and warehouse and pharmacy operations centers in Lancaster, Pennsylvania. WorkSimpli Software LLC leases two office spaces in Puerto Rico.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 88.7% (2024) vs. 87.6% (2023)
• Operating Margin: -7.6% (2024) vs. -9.5% (2023)
• Net Margin: -8.8% (2024) vs. -11.7% (2023)

Investment in Growth:

• R&D Expenditure: $9.5 million (4.5% of revenue) in 2024 vs. $6.1 million (4.0% of revenue) in 2023.
• Capital Expenditures: $11.5 million in 2024 vs. $8.7 million in 2023.
• Strategic Investments:
  • Medifast, Inc. Collaboration: $10 million received from Medifast, Inc. to support platform enhancements, operations, and infrastructure.
  • Capitalized Software Costs: $10.0 million in 2024 for internally developed software.
  • Equipment Purchases: $1.5 million in 2024.

Business Segment Analysis

Telehealth

Financial Performance:

• Revenue: $158.4 million (+61.4% YoY)
• Operating Loss: $(16.8) million
• Operating Margin: -10.6%
• Key Growth Drivers: Increase in online sales demand primarily for LifeMD, Inc. virtual primary care, which experienced a revenue increase of approximately $65.7 million in 2024. Improved pricing also contributed to gross profit.

Product Portfolio:

• LifeMD, Inc.: Virtual primary care and telehealth services for over 200 conditions, including on-demand consultations, prescription medications, diagnostics, imaging, and wellness coaching.
  • GLP-1 Weight Management Program: Rapidly growing offering with over 75,000 patient subscribers as of December 31, 2024, providing GLP-1 medications, lab work, primary care, and metabolic coaching. Expanded in September 2024 to include a non-GLP-1 treatment plan (metformin, bupropion, topiramate).
• Rex MD: Men’s telehealth platform for erectile dysfunction, premature ejaculation, hair loss, weight management, and testosterone replacement therapy. Served approximately 607,000 customers and patients to date.
• ShapiroMD: Legacy brand for male and female hair loss treatment, offering virtual medical treatment, prescription medications, patented doctor-formulated OTC products, topical compounded medications, and FDA-approved medical devices. Served approximately 265,000 customers and patients to date.

Market Dynamics:

• Focus on unaddressed or underserved healthcare needs in virtual primary care, weight loss, men's health, and hair loss.
• Increasing acceptance of commercial insurance and planned Medicare enrollment to broaden market access.
• Strategic partnerships with Withings, Inc. for in-home monitoring and Ash Wellness for at-home lab testing to enhance patient care and data collection.
• Collaboration with Medifast, Inc. to expand access to weight management programs.

Sub-segment Breakdown:

• Telehealth product revenue: $83.4 million (40% of total revenue)
• Telehealth subscription revenue: $70.0 million (33% of total revenue)
• Medifast, Inc. collaboration revenue: $5.0 million (2% of total revenue)

WorkSimpli Software LLC

Financial Performance:

• Revenue: $54.0 million (-0.7% YoY)
• Operating Income: $0.6 million
• Operating Margin: 1.2%
• Key Growth Drivers: Primarily recurring subscriptions (100% of WorkSimpli Software LLC revenue). The slight decrease in revenue was due to lower demand.

Product Portfolio:

• PDFSimpli: Online software as a service platform for creating, editing, converting, signing, and sharing PDF documents.
• ResumeBuild: Provider of digital resume and cover letter services.
• SignSimpli: Digital signature platform.
• LegalSimpli: Provider of legal forms for consumers and small businesses.

Market Dynamics:

• Leading provider of workplace and document services for consumers, gig workers, and small businesses.
• Ranked in the top 25,000 websites globally with over 78 million registrants.
• Approximately 164,000 active subscriptions as of December 31, 2024.
• International net revenues of $14.9 million in 2024.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: No share repurchases in 2024 or 2023.
• Dividend Payments: $3.1 million in preferred stock dividends in 2024 and 2023.
• Dividend Yield: Series A Preferred Stock pays cumulative cash dividends of 8.875% ($2.21875 per share annually based on $25.00 liquidation preference).
• Future Capital Return Commitments: No specific future common stock capital return commitments disclosed.

Balance Sheet Position:

• Cash and Equivalents: $35.0 million (2024) vs. $33.1 million (2023)
• Total Debt: $18.3 million (2024) vs. $18.3 million (2023)
• Net Cash Position: $16.7 million (2024) vs. $14.8 million (2023)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: $8.4 million in principal payments due in 2025 and $10.6 million in 2026 under the Avenue Facility, which matures on October 1, 2026.

Cash Flow Generation:

• Operating Cash Flow: $17.5 million (2024) vs. $8.8 million (2023)
• Free Cash Flow: $6.0 million (2024) vs. $0.1 million (2023)
• Cash Conversion Metrics: Deferred revenue increased by $5.7 million to $14.5 million in 2024, primarily due to increased recurring telehealth subscription revenue. Accounts payable and accrued expenses increased by $11.8 million due to extending payables and credit terms with vendors.

Operational Excellence

Production & Service Model: LifeMD, Inc. operates a direct-to-patient telehealth model, integrating virtual care with prescription and OTC product fulfillment. The company leverages a proprietary technology platform, an affiliated 50-state medical group, and a nationwide pharmacy network. Its wholly-owned affiliated commercial pharmacy in Lancaster, PA, is a state-of-the-art 22,500-square-foot facility designed to fill up to 5,000 daily prescriptions, enhancing the end-to-end care journey. The company also utilizes third parties to manufacture and package its OTC products according to specified formulas and packaging guidelines.

Supply Chain Architecture: Key Suppliers & Partners:

• Fulfillment Services: Utilizes five suppliers for fulfillment services as of December 31, 2024.
• Manufacturing Finished Goods: Utilized nine suppliers for manufacturing finished goods as of December 31, 2023.
• Packaging, Bottling, and Labeling: Utilized seven suppliers for packaging, bottling, and labeling as of December 31, 2023.
• Prescription Medications: Utilized five suppliers for prescription medications as of December 31, 2023.
• Cloud Infrastructure: Amazon Web Services (AWS) for hosting its platform and supporting operations.
• Pharmacy Partners: Maintains relationships with third-party pharmacies for prescription fulfillment, in addition to its wholly-owned LifeMD Pharmacy.
• Technology Partners: CloudBoson Technologies Pvt. Ltd. (formerly LegalSubmit Pvt. Ltd.) for software development services for WorkSimpli Software LLC.

Facility Network:

• Headquarters: New York, New York (lease expires 2028).
• Marketing & Sales: Huntington Beach, California (lease expires 2027).
• Patient Care Center: Greenville, South Carolina (22,500 sq ft, lease expires 2031, with a five-year extension option). Staffed by approximately 126 employees.
• Warehouse & Pharmacy Operations: Lancaster, Pennsylvania (22,500 sq ft, lease expires 2029, with a five-year extension option).
• WorkSimpli Software LLC Offices: Two office spaces in Puerto Rico (leases expire 2026).

Operational Metrics: The Lancaster, PA pharmacy is designed to fill up to 5,000 daily prescriptions and was shipping up to 20,000 orders per month as of Q1 2025. The patient care center includes approximately 126 employees.

Market Access & Customer Relationships

Go-to-Market Strategy: LifeMD, Inc. employs an omni-channel marketing approach to acquire and retain patients and customers at scale. This includes strategic media placements, influencer partnerships, and direct response advertising across national TV, streaming TV, streaming audio, YouTube, podcasts, Out of Home, print, magazines, online search, social media, and digital platforms. The company also leverages its robust customer relationship management (CRM) system and performance marketing platform.

Distribution Channels:

• Direct Sales: Direct-to-patient model through its websites and mobile applications, supported by an in-house patient service and call center.
• Channel Partners:
  • Medifast, Inc.: Utilizes LifeMD, Inc.'s virtual care technology platform to provide its clients access to a clinically supported weight management program.
  • Withings, Inc.: Provides in-home health monitoring devices to LifeMD, Inc.'s GLP-1 weight-loss patients.
  • Ash Wellness: Offers at-home, self-collection laboratory health testing platform to LifeMD, Inc.'s patients.
  • ASCEND Therapeutics, LLC (subsidiary of Besins Healthcare): LifeMD, Inc.'s telehealth services are featured on the www.estrogel.com website to improve access to EstroGel®.
• Digital Platforms: Online sales channels and e-commerce initiatives are central to the direct-to-patient model.

Customer Portfolio:

• Total Customers/Patients: Approximately 1,118,000 individuals served to date.
• Active Patient Subscribers: Approximately 275,000 across primary care, men’s sexual health, weight management, sleep, hair loss, and hormonal therapy.
• LifeMD, Inc. Brand Customers: Approximately 225,000 customers and patients to date.
• Rex MD Customers: Approximately 607,000 customers and patients to date.
• ShapiroMD Customers: Approximately 265,000 customers and patients to date.
• WorkSimpli Software LLC Active Subscriptions: Approximately 164,000 as of December 31, 2024.
• Customer Concentration: No single customer accounted for more than 10% of net sales for the years ended December 31, 2024 and 2023.

Geographic Revenue Distribution:

• International: $14.9 million (2024) and $14.0 million (2023) of total revenue, all related to the WorkSimpli Software LLC segment.
• Growth Markets: The company anticipates entering the international market to meet perceived demand for its offerings.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The telehealth market is described as immature, volatile, and rapidly evolving, with significant structural change and consolidation in the broader U.S. healthcare industry. The GLP-1 medically supported weight loss market is projected to grow from over $13 billion to over $100 billion by 2030 (J.P. Morgan Research). The COVID-19 pandemic increased telehealth utilization, but its long-term impact on demand and regulatory changes remains uncertain. The market is intensely competitive, with numerous online brands, traditional mass merchandisers, drug store chains, independent pharmacies, and traditional healthcare providers expanding into telehealth.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Other established telehealth providers.
• Traditional drug manufacturers and healthcare providers expanding into the telehealth market.
• Traditional pharmacies and large retailers selling non-prescription products (e.g., nutritional supplements, vitamins, hair care treatments).
• New entrants into the direct-to-consumer healthcare market.
• Enterprise-focused companies potentially entering direct-to-consumer healthcare.

Emerging Competitive Threats:

• New competitors or alliances with greater market share, customer base, proprietary technologies, marketing expertise, and financial resources.
• Acquisitions of competitors by third parties with greater resources.
• Traditional healthcare providers pursuing telehealth options paired with in-person capabilities.
• Disruptive technologies or alternative solutions for monitoring, treatment, or prevention of medical conditions.

Competitive Response Strategy: LifeMD, Inc. aims to maintain and grow its market-leading position by focusing on a patient-centric approach, delivering high-quality care, and leveraging its human capital, proprietary technology platform, and unique product offerings. The company plans to continue introducing new differentiated telehealth product and service offerings, such as behavioral health and women's health, and re-launching its virtual primary care program as LifeMD+ with expanded payment options.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Telehealth Market Immaturity: Uncertainty regarding sustained high levels of demand, consumer acceptance, and market adoption. Negative publicity could limit market acceptance.
• Competition: Intense competition from established and new entrants, potentially leading to price competition or making existing offerings obsolete.
• Medication Pricing: Dependence on pricing structures negotiated by drug manufacturers, wholesalers, and pharmacies, which are outside the company's control. Changes in insurance coverage for specific medications could reduce demand or competitive discounts.
• Economic Uncertainty/Downturns: Inflationary pressures, slower growth, or recession could increase costs, reduce customer spending, and limit pharmacy partners' ability to purchase supplies.
• Tariffs and Economic Policies: Can increase raw material costs, disrupt supply chains, and limit product availability, leading to higher prices and reduced sales/profits.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Third-Party Dependency: Reliance on third-party manufacturers, pharmacies, shipping providers, and cloud infrastructure (AWS). Disruptions or termination of these relationships could impair service delivery and increase costs.
• Inventory Damage: Risk of damage to non-prescription inventory stored at facilities, disrupting product delivery.
• Patient Care Center Interruptions: Significant interruptions at the patient care center could lead to lost sales and damage to brand reputation.
• AI Management: Challenges with properly managing AI use could result in reputational harm, competitive harm, and legal liability, including risks related to inaccurate content, discrimination, intellectual property infringement, data privacy, and cybersecurity breaches.

Financial & Regulatory Risks

Market & Financial Risks:

• Net Losses & Profitability: History of net losses, anticipated increasing expenses, and no assurance of achieving or maintaining profitability.
• Leverage: Substantial leverage could adversely affect ability to raise additional capital, limit reaction to industry changes, and expose to interest rate risk.
• Fluctuating Results: Quarterly and annual results may vary significantly due to factors outside control, making forecasting difficult.

Regulatory & Compliance Risks:

• Corporate Practice of Medicine/Fee Splitting: Risk of claims that LifeMD, Inc. is engaged in the corporate practice of medicine or that contractual arrangements with its affiliated medical group constitute unlawful fee splitting, leading to penalties or operational changes.
• Healthcare Fraud and Abuse Laws: Subject to federal and state anti-kickback, false claims, and other healthcare fraud and abuse laws, with potential for significant civil and criminal penalties, exclusion from federal programs, and increased compliance costs.
• Telehealth Laws: Rapidly evolving state laws governing telehealth, remote care, and physician supervision, with potential for restrictions on asynchronous telehealth or remote supervision.
• FDA Regulations: Products and suppliers subject to FDA regulations (FDCA, DSHEA, GMP). Potential restrictions on compounding of GLP-1s (e.g., removal from drug shortage list, addition to "Demonstrable Difficulties for Compounding List") could disrupt patient treatment and adversely impact financial results.
• Unapproved Uses: Risk of fines, penalties, and injunctions if determined to be promoting products for unapproved uses.
• Data Privacy and Security Laws: Subject to numerous federal, state, and foreign privacy and security regulations (HIPAA, HITECH, CCPA, MHMDA). Failure to comply or security breaches could result in significant liability, reputational harm, and increased compliance costs.
• AI Laws: Emerging AI laws and regulations (e.g., Colorado AI Act) could create significant compliance burdens, inhibit product development, or lead to investigations/fines.
• Changes in Healthcare Laws: Public policy changes, healthcare reform legislation (e.g., Health Care Reform Law), or federal budget proposals could materially affect business.

Geopolitical & External Risks

• Geographic Dependencies: Not explicitly detailed beyond U.S. and Puerto Rico operations.
• Trade Relations: Not explicitly detailed.
• Sanctions & Export Controls: Not explicitly detailed.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Proprietary Telehealth Technology Platform: Continuously optimized for scalability, rapid development of new offerings, and flexible infrastructure.
• AI-enabled Support: Leveraged in CRM, patient acquisition, retention capabilities, and real-time data analytics.
• EMR System: Fully integrated for patient clinical data access and compliance.
• Staffing Algorithms: Proprietary algorithms for case-load balancing within the provider network.
• Platform Enhancements: Ongoing investment in technology platform improvements, including for the GLP-1 Weight Management offering (e.g., electronic benefits verification, AI-powered prior authorization optimization, direct integrations with branded manufacturers).

Innovation Pipeline:

• Behavioral Health: Strategic move to broaden service offerings to include teletherapy, psychiatry, and medication management for mental health conditions, with a goal to expand insurance coverage.
• Women’s Health: Focus on menopause and osteoporosis, engaging with renowned specialists to provide holistic, personalized, and accessible care throughout a woman’s lifespan.
• LifeMD+: Re-launch of virtual primary care program to provide low-cost, high-value primary and urgent care, including synchronous and asynchronous 24/7 general wellness, prescription management, available on both cash pay and insurance basis.

Intellectual Property Portfolio:

• Patent Strategy: Two U.S. patents related to ShapiroMD products' method for hair loss treatment with natural ingredients (granted March 24, 2015, and January 3, 2017).
• Trademark Strategy: Registered trademarks include ShapiroMD Hair Growth Experts ® and Cleared ®. Trademark applications are filed and being prosecuted for RexMD, LifeMD, and NavaMD.
• Trade Secret Protection: Relies on trade-secret protection and confidentiality agreements with employees, consultants, and vendors.
• Licensing Programs: Licenses technology and intellectual property from third parties, including open source and trademark licenses for co-branding/co-marketing.

Technology Partnerships:

• Withings, Inc.: Partnership to integrate advanced in-home health monitoring devices for GLP-1 weight-loss patients.
• Ash Wellness: Partnership for at-home, self-collection laboratory health testing platform.
• CloudBoson Technologies Pvt. Ltd.: Provides software development services for WorkSimpli Software LLC.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The company prides itself on hiring and retaining high-quality management and personnel, using equity incentive programs and comprehensive benefits. Succession planning and leadership development initiatives are not explicitly detailed in the provided text.

Board Composition: The Board of Directors includes Justin Schreiber (Chairman), Roberto Simon, John Strawn, Joseph DiTrolio, M.D., Joan LaRovere, M.D., Will Febbo, and Calum MacRae. Specifics on independence, expertise areas, or committee structure are incorporated by reference to the Proxy Statement.

Human Capital Strategy

Workforce Composition:

• Total Employees: 336 employees as of December 31, 2024.
• Full-time Employees: 304 employees as of December 31, 2024 (up from 56 in 2020).
• Part-time Employees: 3 employees as of December 31, 2024.
• Temporary Employees: 29 employees as of December 31, 2024.
• Geographic Distribution: 126 employees are based at the patient care center in Greenville, SC.
• Skill Mix: Focus on recruiting employees in technical functions, public company operations, and to support continued growth.

Talent Management: Acquisition & Retention:

• Hiring Strategy: Focus on hiring individuals with required skills who share the company's mission.
• Retention Metrics: Not explicitly disclosed, but the company expects customer repurchase rates and overall customer retention to strengthen due to investments in customer experience.
• Employee Value Proposition: Equity incentive program for key executive officers and other employees, comprehensive benefits (health insurance, 401(k) match, unlimited paid time off for exempt employees).

Diversity & Development:

• Diversity Metrics: Not explicitly disclosed.
• Development Programs: Employees are supported with training to ensure compliance with policies.
• Culture & Engagement: Adherence to a business code of conduct emphasizing integrity and mutual respect. Most employees are permitted to work remotely.

Environmental & Social Impact

Environmental Commitments: Climate Strategy: Not explicitly detailed in the provided text. Carbon Neutrality: Not explicitly detailed in the provided text. Renewable Energy: Not explicitly detailed in the provided text.

Supply Chain Sustainability: Not explicitly detailed in the provided text.

Social Impact Initiatives:

• Community Investment: Not explicitly detailed in the provided text.
• Product Impact: Mission to empower people to live healthier lives by increasing access to high-quality and affordable virtual and in-home healthcare. Focus on removing barriers to mental health services and providing continuous support throughout a woman’s lifespan with holistic, personalized, and accessible care.

Business Cyclicality & Seasonality

Demand Patterns:

• Seasonal Trends: Not explicitly detailed in the provided text.
• Economic Sensitivity: The business is susceptible to economic uncertainty or downturns, inflationary pressures, and changes in consumer spending on healthcare offerings.
• Industry Cycles: The telehealth market is described as immature and volatile. The GLP-1 medically supported weight loss market is projected for rapid growth.

Planning & Forecasting: Economic uncertainty and macroeconomic conditions make it difficult to accurately forecast and plan future business activities.

Regulatory Environment & Compliance

Regulatory Framework: LifeMD, Inc. operates in a heavily regulated industry, subject to federal, state, and local government laws and regulations. Industry-Specific Regulations:

• FDA and FTC: Heavily regulated by the FDA (Federal Food, Drug and Cosmetic Act, Dietary Supplement Health and Education Act, Good Manufacturing Practice guidelines) and FTC (advertising and product claims).
  • GLP-1 Compounding: Potential FDA restrictions on compounding of GLP-1s (tirzepatide, semaglutide) due to drug shortage list status or addition to the "Demonstrable Difficulties for Compounding List" could disrupt patient treatment and adversely impact financial results.
• Healthcare Fraud and Abuse Laws: Subject to federal and state anti-kickback, false claims (including the civil False Claims Act and CMP Law), and HIPAA criminal healthcare fraud provisions.
• State Licensing Requirements: Certain states regulate companies offering discount medical plans, prescription drug plans, or subscription membership programs.
• State Corporate Practice of Medicine and Fee Splitting Laws: Contractual arrangements with LifeMD Southern Patient Medical Care, P.C. are subject to state laws prohibiting fee splitting or the corporate practice of medicine by lay entities.
• Telehealth Laws: State laws governing remote care, practice of medicine, and healthcare delivery are evolving, with potential restrictions on modalities (e.g., asynchronous telehealth) or remote supervision.

Trade & Export Controls: Not explicitly detailed.

Legal Proceedings:

• Marden v. LifeMD, Inc. (RexMD Brand): A purported putative class action complaint alleging unauthorized disclosure of certain information to third parties, initially filed in New York (dismissed Nov 2024) and refiled in Clark County, Nevada (Nov 2024).
• IRS Notice of Deficiency: IRS asserted an income tax deficiency of approximately $1.9 million for the 2019 tax year. The company disputed this, and IRS Appeals agreed to accept the amended return, resolving the issues in the company's favor.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: The provision for income taxes differs from the U.S. federal income tax rate of 21% due to factors such as state taxes, permanent differences, apportionment of Puerto Rico income, GILTI (net of 250 deduction), dividends received deduction, change in valuation allowance, rate differential, and deferred true-up.
• Geographic Tax Planning: WorkSimpli Software LLC files a tax return in Puerto Rico.
• Tax Reform Impact: Not explicitly detailed beyond the IRS notice of deficiency.
• Net Operating Loss Carryforwards: Approximately $102.8 million of federal NOL carryforwards as of December 31, 2024, which can be carried forward indefinitely but may be subject to Section 382 limitations.
• Valuation Allowance: The company has fully reserved the deferred tax asset resulting from available net operating loss carryforwards, with the valuation allowance increasing by approximately $4.8 million in 2024.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: Maintains product liability insurance coverage, subject to deductibles and limitations. Also maintains insurance covering certain security and privacy damages and claim expenses.
• Risk Transfer Mechanisms: Not explicitly detailed beyond insurance.